Agenus Inc. (NASDAQ:AGEN – Free Report) – Analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Agenus in a research note issued to investors on Wednesday, June 4th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings per share of $0.25 for the quarter, up from their prior estimate of ($0.36). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at $0.41 EPS, FY2026 earnings at $1.16 EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at ($2.36) EPS and FY2029 earnings at ($0.67) EPS.
A number of other brokerages have also weighed in on AGEN. Wall Street Zen upgraded Agenus from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 22nd. B. Riley restated a “buy” rating on shares of Agenus in a research note on Monday, April 21st. Finally, Robert W. Baird raised their target price on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $14.00.
Agenus Stock Performance
Shares of NASDAQ:AGEN opened at $5.95 on Friday. Agenus has a twelve month low of $1.38 and a twelve month high of $18.74. The firm has a market cap of $163.13 million, a PE ratio of -0.53 and a beta of 1.43. The business has a fifty day moving average of $2.97 and a 200-day moving average of $2.96.
Agenus (NASDAQ:AGEN – Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million.
Institutional Trading of Agenus
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. B. Riley Financial Inc. acquired a new stake in Agenus in the fourth quarter worth about $2,074,000. Siren L.L.C. acquired a new stake in Agenus in the first quarter worth about $752,000. AQR Capital Management LLC increased its position in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the period. Gilead Sciences Inc. acquired a new stake in Agenus in the fourth quarter worth about $635,000. Finally, Northern Trust Corp grew its position in shares of Agenus by 14.8% during the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company’s stock worth $572,000 after buying an additional 26,870 shares during the period. 61.46% of the stock is currently owned by institutional investors and hedge funds.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
- Five stocks we like better than Agenus
- Insider Trades May Not Tell You What You Think
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
- How to Read Stock Charts for Beginners
- 3 Oversold Stocks Flashing Bullish Reversal Signals
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- With Novo Nordisk’s CEO Out, Wall Street Wants an American Leader
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.